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1. Introduction 
Stem cell research offers unlimited potential for applications in regenerative medicine. Much 
of the excitement surrounding this area of research comes from the cells inherent qualities; the 
ability to self renew and generate a variety of cells within the body. In the past two decades, 
research on stem cells has progressed exponentially providing a vast array of tools for a large 
breadth of areas. As research persists, there is a growing need for faster and more effective 
tools to analyze the many unknown processes that will unlock the power within these cells.  
Delivery of genes to create labeled stem cells vastly enhances their utility as tools for basic 
research and drug screening but also as potential therapeutic agents. Gene transfer has been 
a routine method in stem cell research since scientists first began culturing stem cells in vitro. 
Genetic manipulation has accelerated research enabling the creation of in vitro models for 
drug discovery, use as a tool for dissecting basic stem cell biology and potential 
development of in vivo cell-based delivery strategies. Efficient gene transfer into stem cells is 
a critical step in the creation of engineered stem cells. Several viral and non-viral methods 
exist for the modification of stem cells, albeit with varying efficiencies (Colosimo et al., 
2000). Each platform has its advantages and disadvantages that can be effectively utilized 
for specific applications.  
Here, we review gene delivery, cloning, and modification methods and describe in detail 
three platforms that enable the user to create modified stem cells that transiently or stably 
express one or multiple genes of interest. The three platforms described here each offer a 
unique feature and advantage that may be ideal for a particular cell type or application. The 
first is a non-integrating insect virus that is ideal for the transient short term expression of 
genes of interest. Second is an episomal EBV based vector method that allows for 
populations of transgene expressing cells to be stably maintained without genomic 
insertion. The third platform is a site specific integrating platform that can be clonally 
selected and is not subject to silencing. 
2. Gene delivery 
Genes carried on plasmid DNA can be introduced into cells with one of the methods listed 
below. The choice of the method largely depends on the size of the DNA plasmid and target 
cell type. Working with stem cells provides a new set of challenges to gene delivery 
requiring substantial optimization. Human embryonic stem cells (hESC) are typically grown 
in tight compact colonies to maintain pluripotency thus requiring transfection methods that 
do not disrupt this. Apart from cell conditions, applications of the gene delivery can direct 
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the method of choice for gene delivery. For cells with downstream clinical applications it is 
essential to use platforms that are “footprint-free” of transgene material. For overexpression 
of specific proteins or knockdown of pathways integrating virus may be ideal and required 
for high copy number insertion. When working with hard to transfect cell types, it is crucial 
to consider all options available.  
2.1 Chemical methods 
Chemical methods utilize lipids, polymers or proteins that form a complex with DNA. This 
condensed complex fuses with the cell membrane thus enabling the entry of the DNA into 
the cells.  
Liposomes remain a popular chemical vehicle for gene delivery in many cell types. In stem 
cells, lipid based methods have been reported with varying efficiencies depending on the 
gene type and cell line (Strulovici et al., 2007). Products like Lipofectamine 2000 (Life 
Technologies) and FuGENE (Roche) are liposomes that utilize the characteristics of chemical 
compounds to form complexes with the DNA/RNA and fuse with the negatively charged 
cell membrane. Lipid methods show reduced toxicity as compared to CaPO4 precipitation 
and earlier transfection protocols. Precipitation methods vary depending on pH and 
uniformity of the precipitate making them an unfavorable mechanism for stem cells. 
Synthetic polymers face similar hurdles. Cell toxicity of the reagent in the target cell type 
remains a limiting factor for chemical methods requiring extensive adaptations and 
optimization.  
2.2 Physical methods 
These methods involve delivery of plasmid across cell membrane using electroporation, 
sonoporation or particle bombardment. Electroporation utilizes electric pulses to transiently 
disrupt the cell membrane to create pores that allows delivery of charged RNA and DNA 
molecules into the targeted cells. This method is highly efficient and primary choice for 
delivery of large constructs into cells. In the recent years specialized electroporation based 
units have emerged. The NucleofectorTM from Lonza utilizes a combination of set programs 
with specific electric parameters and cell-type specific solutions to achieve high levels of 
transfection in several cell types including embryonic stem cells (Lakshmipathy et al., 2004). 
The NeonTM Transfection System from Life Technologies is an open system that allows 
optimization of electrical parameters and the flexibility of using cells from 2X104 to 6X106 
per reaction. This technology avoids the use of standard electroporation cuvette and uses an 
electronic pipette tip as a transfection chamber (Kim et al., 2008). This method has been used 
to create labeled cells with diverse vector platforms in human embryonic stem cells 
(Thyagarajan et al., 2009; Liu et al., 2009). Sound waves or sonoporation has also been used 
to transiently create pores in the cell membrane to deliver nucleic acids into cells (Bao et al., 
1997). Other mechanical methods include manual microinjection of gene into cells (King et 
al., 1994) or particle bombardment using gene guns (Guo et al., 1996) that are effective for 
certain cell types but harsh with the risk of damaging cells.  
2.3 Viral methods 
The use of viral vehicles for gene delivery in mammalian cells has become common practice 
due to the ability of virus to bypass cell membrane with ease. While viral systems retain 
their ability to infect the cells they have been modified to be replication incompetent. This 
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allows for the generation of a recombinant virus that cannot proliferate within the target 
cells. Viral systems infect by a variety of pathways reaching a variety of targets allowing the 
user to choose a virus that best suits the end need.  
Unlike chemical gene transfer, some viral vectors provide a means to directly deliver the 
DNA to the nucleus and in some cases integrate to the genome. While this enhances the 
ability to create a stable cell line, it is also highly variable in copy number and genomic site 
of integration which may cause detrimental effects. Retrovirus and Lentivirus are 
integrating viral systems with the ability to infect a variety of cell types providing stable 
expression of the gene of interest. However, these systems have the ability to recombine 
with genetic material creating replication competent virus. Similarly, Adeno associated 
virus (AAV) provides a mechanism for genomic insertion with the added benefit of site 
specific integration. Conversely, adenovirus has the capability to provide a means of 
transient expression without genomic integration. Adenovirus and AAV are limited by 
genetic capacity of transgene size compared to other viral systems. (Giordano et al., 1999) 
Regardless of adaptations, viral systems remain unfavorable in cells for downstream clinical 
applications. This factor is due to the nature of virus to infect mammalian cells, thus limiting 
their use in cell therapy and other clinical models for stem cells.  
3. Cloning strategies 
Traditional cloning using restriction endonuclease and ligase procedures can be 
cumbersome for large and complex expression vectors. With advances in developmental 
biology there is a need for more intricate cloning systems that can handle customizable and 
high throughput screening through multiple platforms. The cloning procedures described 
below provide a faster and more efficient workflow for directional cloning for a variety of 
uses.  
3.1 TOPO
®
 TA cloning 
The TOPO® TA technology is an efficient method for directionally recombining PCR 
(polymerase chain reaction) products into platform specific vectors. Rather than using 
ligase, the system utilizes vaccinia virus topoisomerase 1, an enzyme involved in the 
digestion and ligation of DNA during replication. TOPO® TA requires a modified plasmid 
equipped with the enzyme covalently bonded to a phosphate on a thymadine at the three 
prime end of the linearized vector. PCR products produced using Taq polymerases have 
three prime and five prime adenine overhangs. This overhang is utilized for the 
recombination with the linearized vector allowing for efficient directional recombination 
within five minutes at room temperature. TOPO® TA is limited by the necessity to create a 
TA adapted linearized vector stock for the TOPO® reactions to occur. TOPO® is not ideal for 
larger inserts showing decreasing efficiency with inserts larger than 5kb. The TOPO ® 
reaction is irreversible and the inserted gene cannot be cloned out by the enzyme. This limits 
the ability to use this gene for other platforms without repeating the PCR (Katzen et al., 
2007).  
3.2 MultiSite Gateway
®
 cloning  
Each of the cell modification platforms below has been outfitted with MultiSite Gateway® 
Technology. Otherwise known as Gateway®, this technology is an efficient and relatively 
easy way to clone multiple gene configurations into a variety of expression vectors. This 
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improves the speed of the cloning process eliminating the need for restriction 
endonuclease cloning procedures. This system harnesses the power of the lambda 
integrase enzyme to recombine multiple fragments in an orientation specific manner with 
high accuracy.  
The lambda integrase recognizes sequence specific recombination sites. Each gene must be 
amplified using Gateway® specific primers containing the proper recombination sites. As 
shown in Figure 1, the building process begins by cloning components of your cassette of 
interest into intermediate vectors. These vectors are recombined with the destination vector 
belonging to your platform of choice. The cloning steps are simple incubation reactions 
speeding up the overall process. 
 
 
 
 
 
Fig. 1. Multisite Gateway® Cloning  
MultiSite Gateway® Technology is a site specific recombinational cloning system where the 
different att specificities allows assembly of 2-4 gene fragments in a defined order and 
orientation. The difference in the att site specificity is determined at the single base level 
(underlined sequence) with virtually no cross recombination between the different sites. 
Here entry clones carrying the gene elements of choice are constructed into a donor vector 
via BP reaction to result in entry clones. Donor vectors with appropriate flanking att sites for 
single or multiple fragment cloning are remised with the right Destination vector and LR 
reaction performed to yield final expression vectors.  
Outfitting a variety of platforms with Multisite Gateway® technology makes the transition 
between technologies a simple cloning reaction. Each expression cassette can be cloned into 
a variety of destination vectors expanding your ability to modify cells based on specific 
needs. Thus, the user can create a library of gene cassettes that can be readily used for a 
variety of applications. The dual arrows in Figure 1 indicate that Multisite Gateway® 
provides a reversible reaction (under different conditions) that retains the rapid cloning 
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features of the TOPO® TA system. Using Multisite Gateway® we traverse a variety of cell 
modifying systems, based on need, with ease and speed.   
4. Cell modification platforms 
Besides efficient gene transfer into stem cells, a critical step is the choice of platform used to 
create labeled cells. Traditionally, naked plasmid DNA is used to create stable clones, but is  
less favored in stem cells due to varied expression levels depending on the context of its 
genomic integration. (Eiges et al., 2001) To overcome this issue, lentiviral methods that offer 
higher transduction rates and multiple integrations have been used to generate stable 
transgene expressing cells (Jang et al., 2006). A major limitation of lentiviral systems is the 
size or payload of DNA that can be packaged. Recently, methods that result in efficient 
random integration via transposases and site-specific genomic integration mediated via 
adeno-associated viruses (AAV), and site-specific integrases, have been reported as a means 
to modify stem cells (Surosky et al., 1997, Kowabata et al, 2006).  
Site-specific integration offers an elegant method to generate clones with one copy of the 
gene at a specific genomic location that can be further screened to identify ideal sites that 
support sustained gene expression. This method require the isolation of clonal population of 
cells followed by rigorous characterization of the genomic integration site to ensure 
sustained transgene expression and is best suited for cell types that can be cultured for long 
periods of time. Embryonic stem cells and other cell lines, with unlimited proliferative 
potential, can be subjected to such methods to create engineered cells expressing the gene of 
interest. JumpInTM platform utilizes phiC31 and R4 integrases to target pseudo sites in the 
mammalian genome that are known to support higher and longer-term expression of 
inserted transgenes. This method requires prolonged culture and is manipulation and ideal 
to create labeled pluripotent stem cells for sustained gene expression both in pluripotent 
state as well as differentiation.  
EBV-based vectors support episomal maintenance of large genomic fragments and hence are 
an appealing alternative to rapidly generate labeled cells. Since the plasmid is not integrated 
into the host genome, expression of the transgene is relatively free from chromosomal effects 
associated with genomic integration. This method requires drug selection but not clonal 
isolation. Pooled clones can therefore be rapidly generated and suited for expression of 
genes or knocked down in the undifferentiated state. Since there is a risk of loss of 
transgene/plasmid in the absence of selective pressure, labeled pluripotent stem cells will 
result in attenuated transgene expression with long term differentiation.  
Both the methods highlighted above require transfection of plasmid into cells and 
prolonged manipulation and culture, a feature not amenable to most primary and adult 
stem cell types due to their limited proliferation. BacMam offers an easy and fast method to 
deliver transgenes into a wide spectrum of stem cells with the least toxicity. The introduced 
transgene is diluted with passage and therefore ideal for transient expression to create 
assay-ready cells. Figure 2 displays a comparison of transient (BacMam), stable non-
integrating (EBV-Vector), and integrating platforms(Jump-InTM). 
The three platforms discussed here are; Episomal vectors that results in stable retention of 
the plasmid (green circles) without integration into the genome; JumpInTM platform that 
allows site-specific insertion of the gene (shown in green) into the host genome for stable 
expression and; BacMam, a viral method where the transgene does not integrate into the 
host genome (Green circles) but dilutes out as cell divides and hence transient. 
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Fig. 2. Labeling Platforms 
4.1 BacMam 
Transient expression systems are ideal for rapidly creating labeled cells for immediate 
utilization in downstream applications such as cell tracking, identification, enrichment, drug 
screening and other types of high throughput assays. Traditionally lipid-based methods 
have been used to introduce DNA carrying the gene of interest. This method, however, is 
not amenable to certain cell types, especially primary and stem cells that are generally hard 
to transfect. Baculoviruses are known to enable high efficiency labeling of hard to label cells 
with minimal toxicity (Zeng et al., 2009, Ho et al.,2005). These viruses are non-replicating in 
human cells and are stable at 4°C and thus easy to generate and use.  
 The BacMam platform, named for the ability of Baculovirus to transfect Mammalian cell 
types, is a double stranded DNA virus capable of infecting over 500 insect species. The DNA 
is packaged in a rod-shaped particle 40-50 nm in diameter and 200-400 nm in length. Gp64, a 
major glycoprotein on the envelope, is proposed to play a key role in virus attachment and 
entry into mammalian cells. The viral particles are endocytoced and are released into the 
cytoplasm before migrating to the nucleus.  
 BacMam is non-replicating in mammalian cells without any additional modifications. This 
is contrast to other viral methods such as lenti, adeno, or retro that integrate into the host 
genome and requires inactivation of key attributes of the virus to prevent unwanted 
replication within cells. In addition, integrating viral constructs also have the chance of 
recombining with endogenous sequences in the human genome resulting in instability. The 
ease of use, high efficiency of labeling and relatively low toxicity renders BacMam an ideal 
choice for primary, stem and progenitor cells. In addition, their ability to carry high load 
capacity reaching upwards of 30kb sequences adds to its appeal for simultaneous delivery 
of single or multiple genes of interest.  
The most commonly used method to generate BacMam virus is the Bac-to-Bac® method 
where the gene of interest is first cloned into a transfer vector. The cloning and production 
process are shown in Figure 3A. This transfer vector could be created by either by 
Restriction endonuclease mediated cloning (pFastBacTM) or MultiSite Gateway® adapted 
(pDest). Once the expression vector is constructed, it is transformed into a modified E coli 
that contains a baculovirus genome. Recombination of the transfer vector with the 
baculovirus genome results in BacMid which is ready for transfection into insect cells for 
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virus production. BacMid is transfected into Sf21 (Spodoptera frugiperda) insect cells. The 
production is limited by variability of the virus which results in testing a variety of clones. 
Despite the selection of multiples clones, there is a necessity for plaque purification of the 
virus to ensure a clone is selected with the expression cassette. 
 
 
Fig. 3. BacMam  
(A) Gene of interest is cloned into the baculovirus transfer vector using MultiSite Gateway® 
cloning. The resulting expression vector is transformed into DH10BacTM to generate BacMid 
via site-specific transposition of the expression elements on the transfer vector to the 
baculovirus genome present in DH10Bac cells. Transfection of BacMid DNA into Sf9 or Sf21 
insect cells results in BacMam virus carrying the expression cassette that can be further 
amplified in insect cells to generate high titer stocks. (B) BacMam carrying the expression 
cassette CMV-GFP can be transduced into undifferentiated H9 hESC either on feeders or 
feeder-free conditions. Cells that are induced to differentiate for 1-2 weeks can also be 
transduced by BacMam and GFP labeled cells colocalize with lineage specific markers. 
The ability to transduce a variety of cells types makes BacMam an ideal system for 
expression in partially or terminally differentiated cells derived from embryonic stem cells 
(Figure 3B). These cells have a limited proliferation preventing their use with selectable 
markers that require clone establishment. Transduction of differentiating ESC with GFP 
BacMam and overlap with differentiation markers has been demonstrated.  
BacMam provides an easy to clone, easy to use, non-integrating transfection system. 
However, this system may not be ideal for long term gene expression in dividing cell types. 
The inability to replicate may be a limitation of the technology since the signal will dilute 
out in rapidly dividing cells. Additionally, for downstream clinical applications it may 
undesirable to use a viral system despite its inability to infect mammalian cells.  
4.2 Episomal vectors 
With the ability of stem cells to divide indefinitely it is essential to have a platform that can 
express long term. Generating labeled stem cell lines provides a valuable tool for research. 
However the creation of stable lines is complicated by stability and copy number of the loci. 
Technologies for this purpose have been reviewed using viral, homologous recombination 
and integrase specific integrations (Yates et al., 2006). Plasmid DNA alone has been utilized 
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to randomly integrate for a fast way to create a labeled line. Lentivirus works efficiently due 
to multiple copy insertion into the genome. However, this can have negative effects. Thus, 
there is a need for a stable line that does not have any genomic alterations or silencing 
issues. To overcome these problems, an episomally maintained DNA vector for stably 
expressing stem cell lines is used.  
The Epstein Bar Virus (EBV), a member of the herpes virus family, is known to infect 
multiple cells types and remains one the of the most common virus in humans. EBV based 
episomal vectors have been successfully used to stably express gene of interest in multiple 
types of cells both in vitro and in vivo since 1985 (Yates et al., 1985). The crucial components 
of the viral genome that have been added to vector systems are the latent origin of 
replication (OriP) and the EBV Nuclear Antigen-1 region (EBNA). These elements are 
required in combination for stable maintenance of episomal plasmid DNA. The trans acting 
element, EBNA, cannot function without the cis acting element, OriP. Additionally, the 
EBNA-OriP combination is only functional in human, primate and canine cells. 
Reproduction of extrachromosomal replication using the EBNA1 has also been reported in 
murine models, however, this requires the additional expression of transgenes (Habel et al., 
2004).  
In hESC these vectors have had relative levels of success using a two step system first 
creating a stable EBNA1 expressing cell line and transfecting a OriP vector (Ren et al., 2006). 
This however does not mitigate the problem of silencing from genomic integration. The 
EBNA oriP destination vector (Figure 4A) is a one step vector system that includes both 
elements eliminating the need for an EBNA cell line step. The ability to express high levels 
of transgenes without genomic integration provides a useful system for downstream clinical 
applications. Recently, episomal vector systems using the EBNA OriP elements have been 
reported for the generation of induced pluripotent stem cells (Yu et al., 2009). 
Reprogramming by the forced expression of multiple transcription factors is an ideal 
example of the power of the episomal vector outfitted with MultiSite Gateway® technology. 
Multiple configurations can be created in a high throughput manner allowing for the 
adaptations of expression, stoichemetry and exchange of alternate genes.  
Episomal vectors replicate once per cell cycle with activation of replication by binding of 
multiple EBNA1 homodimers to OriP. Similar to BacMam, this system offers an appealing 
alternative to integrating technologies since they are relatively free from chromosomal 
effects associated with genomic integration. These vectors, being rather larger in size (over 
10 kb) can be transfected into embryonic and adult stem cells such as MSC albeit with lower 
efficiencies. Since the distribution of episomal vectors with cell division is unequal between 
the daughter cells, it is best to keep cells under selective pressure for sustained gene 
expression. It is also not necessary to generate individual clones; drug resistant colonies 
obtained can be pooled to rapidly create labeled cells for downstream applications. 
Episomal vectors have been used to generate stable hESC pooled clones that maintain 
transgene expression for long periods of time. Genes driven by constitutive or lineage 
specific promoters have been shown to express in a context specific matter (Figure 4B). In 
addition, majority of the cells retain transgene expression when induced to differentiate in 
the absence of selective pressure for 3 weeks (Thyagarajan et al., 2009).  
Episomal vectors provide an easy platform to rapidly create stable cells expressing 
transgene of interest. A major limitation of this method is the requirement for efficient 
transfection method and pooled clones that have varying copy numbers per cell thereby 
creating a heterogeneity in expression levels that may be undesirable for certain 
applications. 
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Fig. 4. Episomal Vectors.  
(A) Epstein Barr virus based vectors contain Epstein-Barr virus nuclear antigen (EBNA1) 
and the latent origin of replication OriP that help in episomal maintenance of the vectors by 
facilitating the replication of the vectors once per cell cycle by binding of the multiple 
EBNA1 homodimers to OriP. Mutlisite Gateway® adaption of these vectors allow rapid 
assembly of single or multiple gene elements and a Hygromycin resistance gene provides a 
means to maintain selective pressure on cells carrying these vectors. (B) Human ESC can be 
transfected with episomal vectors to create stable pooled clones expressing GFP or gene of 
interest driven by constitutive promoters such as Ef1a or lineage specific promoter such as 
the pluripotent cell specific Oct4.  
4.3 Jump-In
TM
 technology 
As research uncovers the potential of stem cell research there are many applications that 
require a clonal population expressing a custom cassette. Transgene cassettes can vary from 
lineage reporter lines, to multicistronic elements or even systems useful for higher content 
analysis. These complex tools will require single copy integration of the expression cassette 
with resistance to silencing. Single copy cell lines have been reported in human embryonic 
stem cells using homologous recombination, cre/lox mediated integration and zinc finger 
site directed integration (Costa et al., 2007, Lombardo et al., 2007, Soldner et al., 2009). 
Homologous recombination can lead to random integration as well as silencing depending 
on the locus. Unlike homologous recombination, non-viral integrases have the potential to 
recombine two non-identical sites. Zinc finger has been proven as an accurate method, 
however, require designing sequence specific zinc finger for recombination (Lombardo et 
al., 2007).  
The Jump In system uses non-viral integrase-mediated site-specific integration to develop a 
platform stem cell line. The two integrases phiC31 and R4 are both members of the 
Streptomyces family with the potential to integrate transgenes to native attP (attachment P 
site) sites that are present in the bacterial genome or pseudo attP sites that are present in 
other species such as human, rat and mouse. Although there are a variety of pseudo attP 
sites within the human genome, certain hot spots have high affinity for recombination. This 
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results in a very low background of non site specific targeting. A pseudo attP hot spot on 
chromosome 13 has provided an ideal location due to the known intronic areas of the 
chromosome. Many other gene delivery methods are affected by chromatin remodeling 
during differentiation. The chromosome 13 loci has been shown to remain active throughout 
differentiation to multiple lineages remaining resistant to silencing. The system has a much 
higher efficiency for large complex fragments. 
Delivered via electroporation, the vectors introduce large complex gene cassettes to a specific 
genomic locus validated for efficiency, stability, transcriptional activity and resistance to 
silencing (Liu et al., 2009). The phiC31 integrase is employed to insert a native R4 attP site into 
the genome that can be accessed for future recombination. R4 integrase mediated integration 
occurs at the new R4 attP site activating the expression of a selection marker. Figure 5 shows 
stepwise creation of the target line and subsequent retargeting that results in activation of the 
Zeomycin gene. Stable clones can be selected and expanded for further validation.  
 
Fig. 5. Site Specific Integration 
(A) A Target plasmid containing the wild type R4 integrase recognition (attP) site carrying a 
constitutive expressed antibiotic gene with a PhiC31 integrase attB site is transfected into 
cells along with a plasmid expressing phiC31 integrase. The enzyme catalyzes the 
integration of the target plasmid into “Pseudo attP sites” within the host cellular genome. 
Also contained on the Target plasmid is a promoterless antibiotic gene. The constitutive 
expressed antibiotic is used to select stable drug resistant clones and screened for single 
copy and genomic site of integration. (B) Clones carrying a single copy of the target plasmid 
in a desired genomic locus are retargeted. A retargeting plasmid carrying the promoter-gene 
expression cassette, a promoter adjacent to a R4 attB site and a plasmid expressing R4 
integrase is transfected. (c) R4 integrase mediated retargeting will result in positioning of the 
promoter adjacent to the drug resistance gene placed in the original Target cells to activate 
the antibiotic gene which can then be utilized to generate drug resistant clones.  
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With single copy integration there is less variability between copy number and expression 
patterns if trying to express multiple genes. The technology has been reported for potential 
lineage tracking by expressing GFP from an Ef1alpha promoter throughout differentiation 
without silencing.  
Although this platform has proven to be an accurate and efficient way to modify stem cells 
there are still improvements that can be made. The technology still shows a tendency to 
randomly integrate plasmid sequences leaving the need to verify copy number and 
integration sites via molecular techniques.  
5. Conclusion 
Gene modification provides researchers with tools to accurately dissect cellular function. 
The techniques described offer a toolbox with interchangeable components to create specific 
assays for specific applications. Utility of the various available platforms depends on several 
factors. First is to determine the desired length of expression needed for the desired 
application. Second, it is important that the cell type to be modified is amenable to gene 
delivery methods either via transfection or via specific viral methods. Third, the 
proliferative capability of cells that are being modified is important to determine if these 
cells can sustain long periods of manipulation and drug selection and if the resulting 
modified cells will retain their original stem cell characteristics.  
The three platforms summarized in this chapter each have their advantages and 
disadvantages. The most notable difference between the three is the length of time and 
amount of manipulation required for generation of the labeled cells (Table 1). Starting from 
a vial of frozen pluripotent stem cells, 2-3 week is needed to recover and expand enough 
cells, typically atleast 6-10 million cells for the first step. For transient expression using 
BacMam, cells are ready for use 24-48 h post transduction. With EBV-episomal vector, cells 
after transfection are subjected to drug selection and resulting pooled clones to be 
characterized. This entire process of generating stable clones is approximately 8 weeks long. 
The Jump-InTM platform that requires two rounds of transfection, drug selection and 
subsequent characterization requires approximately 15 weeks to obtain modified stem cells.  
Choice of platform to use is not merely based on ease or length of creating labeled cells. It is 
important to understand the advantages and disadvantages of each method so that features 
ideal for the application of interest is used to create modified stem cells (Table 2). BacMam 
enables efficient delivery into diverse cell types and is the fastest method to create labeled 
cells. However the expression is transient and since workflow does not involve drug 
selection resulting cells will have variable expression depending on the number of copies 
they carry. This method is therefore ideal for delivery of target to create assay ready cells for 
experiments that can be completed within 24-48 h after creation of the labeled cells. This 
method however is not suitable for expressing genes and monitoring its long term effect on 
the cells. Episomal vectors offer the advantage of creating stable pooled clones in a relatively 
short period of time. Disadvantages of this method are that transfection into hard to 
transfect cells remains an issue and since copy number is variable expression can be 
heterogeneous and expression level may be attenuated with long term differentiation. 
Finally Jump-InTM system is ideal for creation of stable pluripotent stem cells for sustained 
expression both in its undifferentiated state and with differentiation. The ability of this 
system to create clones with a single copy of the gene at a known genomic locus makes this 
an ideal choice for use of this line as a Platform line into which diverse targets can be 
inserted for comparison all from the same genomic context.  
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Recently efforts are focused on creating hybrid systems to generate novel engineering 
method which overcome some of the limitation for the system. EBV-elements EBNA and 
OriP cloned into BacMam transfer vectors to generate EBNA BacMam has easy delivery but 
also sustained gene expression. The ultimate goal is to create labeled cells that can be used 
for the end application. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Steps and Duration of the Cell Engineering Methods 
The length in time to generate labeled cells varies between the three methods 
(highlighted in the color bars) 
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Table 2. Summary of cell engineering methods 
Advantages and disadvantages of each method and potential application of each method  
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of a new approach to the treatment of genetic and developmental human diseases. Due to the fact that
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their conversion into functionally mature tissue, are not necessarily seeking to result in the clinical application
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natural process of development of mature cells from their immature progenitors during the embryonic period
onwards, which can produce valuable results as knowledge of the developmental processes during
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cancer is one of the leading causes of death throughout the world, highlights the importance of these
researches in the fields of biology and medicine.
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